Version history

{
  "session_id": "sess-hyp-24b92eb41b48",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "llm",
  "action": "synthesize",
  "content": "\n\n# Scientific Hypothesis Synthesis & Evaluation\n\n## Hypothesis Summary\n**SCFA Deficiency Drives Microglial Hyperactivation via GPR43/NF-κB Dysregulation**\n\nThe hypothesis posits that gut dysbiosis depletes SCFA-producing commensals, reducing SCFA-mediated activation of microglial GPR43/GPR41 receptors and HDAC inhibition. This removes inhibitory checkpoints on NF-κB, permitting unchecked pro-inflammatory cytokine production.\n\n---\n\n## Dimension Scores\n\n| Dimension | Score | Rationale |\n|-----------|-------|-----------|\n| **Mechanistic Plausibility** | **0.81** | Logically coherent pathway; integrates receptor-mediated G-protein signaling with epigenetic regulation. GPR43/41 → NF-κB axis is biologically supported, though HDAC3 specificity in microglia requires validation. |\n| **Evidence Strength** | **0.72** | Strong biochemical evidence for SCFA-HDAC-NF-κB relationships. Moderate evidence from germ-free/antibiotic mouse models. Limited direct human evidence; causality in neurodegeneration remains associative. |\n| **Novelty** | **0.65** | Modestly novel; builds on established gut-brain axis literature. The dual braking mechanism (receptor + epigenetic) adds conceptual refinement rather than paradigm shift. |\n| **Feasibility** | **0.78** | Highly testable in animal models (GF mice, FMT, SCFA supplementation). Human translational studies are feasible but expensive. GPR43 knockout/agonist studies are technically mature. |\n| **Therapeutic Potential** | **0.84** | High potential: butyrate supplementation, prebiotics, probiotics, GPR43 agonists. Blood-brain barrier",
  "tokens_used": "396",
  "persona_id": "persona-synthesizer"
}